Abstract
Purpose
Angiogenesis is an essential process for the expansion of multiple myeloma (MM). Angiopoietin-2 (Ang-2), Ang-1 and their receptor possess important roles in this procedure. The aim of the study was to measure serum levels of Ang-2 along with known markers of angiogenesis and to estimate their prognostic impact on the survival.
Methods
Bone marrow microvascular density (MVD), estimated by CD31, and circulating levels of known angiogenic factors Ang-2, interleukin-6, soluble CD105 and platelet-derived growth factor-AB, measured by ELISA, were measured in 77 newly diagnosed patients with active MM and in 57 of them who responded to chemotherapy.
Results
All measured parameters were increased in MM patients, were also increasing in advanced disease and decreased after effective treatment. Ang-2 correlated positively with the other angiogenic factors and MVD. Moreover, Ang-2 values above the median were accompanied by worse survival.
Conclusion
Ang-2 correlates strongly with the angiogenic process and its serum levels are importantly prognostic for survival, highlighting the role of angiopoietins pathway in the biology of MM.
Similar content being viewed by others
References
Agnelli L, Bicciato S, Mattioli M et al (2005) Molecular classification of multiple myeloma: a distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations. J Clin Oncol 23:7296–7306
Anargyrou K, Terpos E, Vassilakopoulos TP et al (2008) Normalization of the serum angiopoietin-1 to angiopoietin-2 ratio reflects response in refractory/resistant multiple myeloma patients treated with bortezomib. Haematologica 93:451–454
Bhaskar A, Gupta R, Vishnubhatla S et al (2013a) Angiopoietins as biomarker of disease activity and response to therapy in multiple myeloma. Leuk Lymphoma 54:1473–1478
Bhaskar A, Gupta R, Sreenivas V et al (2013b) Synergistic effect of vascular endothelial growth factor and angiopoietin-2 on progression free survival in multiple myeloma. Leuk Res 37:410–415
Dong X, Han ZC, Yang R (2007) Angiogenesis and antiangiogenic therapy in hematologic malignancies. Crit Rev Oncol Hematol 62:105–118
Duff SE, Li C, Garlang JM, Kumar S (2003) CD105 is important for angiogenesis: evidence and potential applications. FASEB J 17:984–992
Folkman J, Klagsbrun M (1987) Angiogenic factors. Science 235:442–447
Giuliani N, Colla S, Lazzaretti M et al (2003) Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 102:638–645
Holash J, Wiegand SJ, Yancopoulos GD (1999) New model of tumour angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 118:5356–5362
Loughna S, Sato TN (2001) Angiopoietin and Tie signalling pathways in vascular development. Matrix Biol 20:319–325
Maisonpierre PC, Suri C, Jones PF et al (1997) Angiopoietin-2, a natural antagonist for Tie-2 that disrupts in vivo angiogenesis. Science 277:55–60
Mitsiades CS, Mitsiades NS, Munshi NC, Richardson PG, Anderson KC (2006) The role of the bone marrow microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer 42:1564–1573
Papetti M, Herman IM (2001) Mechanism of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 282:947–970
Pappa CA, Tsirakis G, Samiotakis P et al (2013a) Serum levels of angiopoietin-2 are associated with the growth of multiple myeloma. Cancer Invest 31:385–389
Pappa C, Alexandrakis M, Boula A et al (2013b) Emerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients. Hematol Oncol. doi:10.1002/hon.2044
Plank MJ, Sleeman BD, Jones PF (2004) The role of the angiopoietins in tumour angiogenesis. Growth Factors 22:1–11
Quartarone E, Alonci A, Allegra A et al (2006) Differential levels of soluble angiopoietin-2 and Tie-2 in patients with haematological malignancies. Eur J Haematol 77:480–485
Scharpfenecker M, Fiedler U, Reiss Y, Augustin HG (2005) The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through and internal autocrine loop mechanism. J Cell Sci 118:771–780
Sezer O, Niemoller K, Eucker J et al (2000) Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 79:574–577
Terpos E, Anargyrou K, Katodritou E et al (2012) Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents. Int J Cancer 130:735–742
Thurston G (2002) Complementary actions of VEGF and angio-poietin-1 on blood vessel growth and leakage. J Anat 200:575–580
Tsirakis G, Pappa CA, Spanoudakis M et al (2012a) Clinical significance of sCD105 in angiogenesis and disease activity in multiple myeloma. Eur J Int Med 23:368–373
Tsirakis G, Pappa C, Kanellou P et al (2012b) Role of platelet-derived growth factor-AB in tumour growth and angiogenesis in relation with other angiogenic cytokines in multiple myeloma. Hematol Oncol 30:131–136
Uneda S, Matsuno F, Sonoki T et al (2003) Expression of vascular endothelial factor and angiopoietin-2 in myeloma cells. Haematologica 88:113–115
Yancopoulos GD, Davis S, Gale NW et al (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248
Ethical standard
This study has been approved by our institute ethics committee and has therefore been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. All persons gave their informed consent prior to their inclusion in the study.
Conflict of interest
We declare that we have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pappa, C.A., Alexandrakis, M.G., Boula, A. et al. Prognostic impact of angiopoietin-2 in multiple myeloma. J Cancer Res Clin Oncol 140, 1801–1805 (2014). https://doi.org/10.1007/s00432-014-1731-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-014-1731-2